1. Home
  2. EPAC vs IBRX Comparison

EPAC vs IBRX Comparison

Compare EPAC & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EPAC
  • IBRX
  • Stock Information
  • Founded
  • EPAC 1910
  • IBRX 2014
  • Country
  • EPAC United States
  • IBRX United States
  • Employees
  • EPAC N/A
  • IBRX N/A
  • Industry
  • EPAC Industrial Machinery/Components
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • EPAC Technology
  • IBRX Health Care
  • Exchange
  • EPAC Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • EPAC 2.6B
  • IBRX 2.4B
  • IPO Year
  • EPAC N/A
  • IBRX N/A
  • Fundamental
  • Price
  • EPAC $48.73
  • IBRX $5.10
  • Analyst Decision
  • EPAC
  • IBRX Buy
  • Analyst Count
  • EPAC 0
  • IBRX 2
  • Target Price
  • EPAC N/A
  • IBRX $17.38
  • AVG Volume (30 Days)
  • EPAC 354.1K
  • IBRX 7.2M
  • Earning Date
  • EPAC 12-17-2024
  • IBRX 11-12-2024
  • Dividend Yield
  • EPAC 0.08%
  • IBRX N/A
  • EPS Growth
  • EPAC 91.76
  • IBRX N/A
  • EPS
  • EPAC 1.56
  • IBRX N/A
  • Revenue
  • EPAC $589,510,000.00
  • IBRX $7,332,000.00
  • Revenue This Year
  • EPAC $7.26
  • IBRX $1,563.18
  • Revenue Next Year
  • EPAC $6.07
  • IBRX $1,262.20
  • P/E Ratio
  • EPAC $32.49
  • IBRX N/A
  • Revenue Growth
  • EPAC N/A
  • IBRX 1218.71
  • 52 Week Low
  • EPAC $27.06
  • IBRX $3.10
  • 52 Week High
  • EPAC $51.91
  • IBRX $10.53
  • Technical
  • Relative Strength Index (RSI)
  • EPAC 61.19
  • IBRX 54.10
  • Support Level
  • EPAC $46.41
  • IBRX $4.80
  • Resistance Level
  • EPAC $51.91
  • IBRX $5.38
  • Average True Range (ATR)
  • EPAC 1.26
  • IBRX 0.49
  • MACD
  • EPAC -0.25
  • IBRX -0.07
  • Stochastic Oscillator
  • EPAC 51.30
  • IBRX 46.21

About EPAC Enerpac Tool Group Corp.

Enerpac Tool Group provides high-precision tools, controlled-force products, and solutions for precise heavy lifting. The company has one reportable segment, the Industrial Tools & Services (IT&S) Segment. The IT&S segment is primarily engaged in the design, manufacture, and distribution of branded hydraulic and mechanical tools and in providing services and tool rental to the refinery/petrochemical; general industrial; industrial maintenance, repair, and operations (MRO); machining & manufacturing; power generation; infrastructure; mining; and other markets. Geographically, the company has operations in Algeria, Australia, Brazil, France, Germany, Kazakhstan, India, Italy, Japan, Norway, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Spain, and the United Arab Emirates.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Share on Social Networks: